NasdaqGS - Nasdaq Real Time Price USD

Olema Pharmaceuticals, Inc. (OLMA)

9.52 -0.32 (-3.25%)
At close: 4:00 PM EDT
9.52 0.00 (0.00%)
After hours: 4:02 PM EDT
Loading Chart for OLMA
DELL
  • Previous Close 9.84
  • Open 9.76
  • Bid 7.03 x 200
  • Ask 11.92 x 200
  • Day's Range 9.26 - 9.81
  • 52 Week Range 5.02 - 17.79
  • Volume 510,671
  • Avg. Volume 838,032
  • Market Cap (intraday) 532.49M
  • Beta (5Y Monthly) 2.10
  • PE Ratio (TTM) --
  • EPS (TTM) -2.00
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 25.75

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

olema.com

75

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OLMA

Performance Overview: OLMA

Trailing total returns as of 5/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

OLMA
32.15%
S&P 500
11.29%

1-Year Return

OLMA
38.98%
S&P 500
26.63%

3-Year Return

OLMA
60.84%
S&P 500
28.97%

5-Year Return

OLMA
78.84%
S&P 500
48.19%

Compare To: OLMA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OLMA

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    550.39M

  • Enterprise Value

    303.62M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.33

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.61%

  • Return on Equity (ttm)

    -48.31%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -99.34M

  • Diluted EPS (ttm)

    -2.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    248.98M

  • Total Debt/Equity (mrq)

    0.93%

  • Levered Free Cash Flow (ttm)

    -45.57M

Research Analysis: OLMA

Company Insights: OLMA

Research Reports: OLMA

People Also Watch